Skip to main content
. 2021 Mar;7(1):68–82. doi: 10.21037/jss-20-625

Table 2. Surgical characteristics, secondary endpoints (except physiological parameters) and follow-up of the study population.

Total (n=50) BKP Group (n=25) PS Group (n=25) 95% CI P value
Fractured vertebrae, n 61 29 32
Number of fractured vertebrae, mean ± SD [range] 1.2±0.5 [1–3] 1.2±0.5 [1–3] 1.3±0.5 [1–3] −0.1690 to 0.4090 0.408
Number of surgically approached vertebrae, mean ± SD [range] 3.4±2.1 [1–8] 1.6±0.9 [1–3] 5.2±1.1 [3–8] 2.933–4.107 <0.001
Pedicle screws inserted, n 200 0 200
Extent of instrumentation for single-level fractures, n [%]
   Short fixation (one level above and below index level) 1 [2] 1 [4]
   Short fixation (two level above and one below index level) 4 [8] 4 [16]
   Long fixation (two levels above and below index level) 12 [24] 12 [48]
   Other, n [%] 2 [4] 2 [8]
Cement augmentation of pedicle screws, n [%] 21 [42] 21 [84]
Vertebral body augmentation with BKP, n [%] 47 [94] 25 [100] 22 [88]
   Single-staged 48 [96] 25 [100] 23 [92]
   Two-staged 2 [4] 0 [0] 2 [8]
Protective vertebroplasty of unfractured adjacent vertebrae, n [%] 12 [24] 7 [28] 5 [20] 0.508
Resident involved (teaching case), n [%] 39 [78] 19 [76] 20 [80] 0.733
Intraoperative complications, n [%] 0 [0] 0 [0] 0 [0] 1.000
Cement leakage 18 [36] 7 [28] 11 [44] 0.196
   Intraspinal 2 [4] 2 [8] 0 [0] 0.490
   Ventral or lateral confined to level 14 [28] 5 [20] 9 [36] 0.208
   Ventral or lateral >1 level 1 [2] 0 [0] 1 [4] 1.000
   Adjacent disc space 1 [2] 0 [0] 1 [4] 1.000
Surgical time (min), mean ± SD [range] 108.5±70.2 [23–274] 52±32.9 [23–165] 164.9±48.4 [51–274] 89.344–136.416 <0.001
   Surgical time (min) per level approached, mean ± SD [range] 32.4±9.5 [15–60] 32.7±10.5 [15–60] 32.2±8.5 [17–54.8] −5.928 to 4.960 0.859
Length of stay (days), mean ± SD [range] 5.6±3 [1- 16] 4.3±2.5 [1–10] 7±2.9 [3–16] 1.149–4.211 0.001
Opioid use at discharge, n [%] 34 [68] 13 [52] 21 [84] 0.015
30-day readmission rate, n [%] 3 [6] 2 [8] 1 [4] 1.000
Surgical site infections during follow-up, n [%] 0 [0] 0 [0] 0 [0]
Follow-up (months), mean ± SD [range] 8.4±11.8 [1–56.4] 8±13.4 [1–56.4] 8.8±10.2 [1.3–43.6] −6.0165 to 7.5045 0.826
Opioid use at 3-month follow-up, n [%] 7 [14] 3 [12] 4 [16] 1.000
NRS (0-10) at 3-month follow-up, mean ± SD [range] 2.4±1.8 [0–5.5] 2.6±1.9 [0–5.5] 2.2±1.8 [0–5.5] −1.4522 to 0.6522 0.448
Subsequent fractures within 3-month follow-up, n [%] 20 [40] 11 [44] 9 [36] 0.564

, surgical times were summarized for two-staged procedures in 2 patients in the PS group. , P value from Fisher’s Exact test. CI, confidence interval; SD, standard deviation.